Pain Therapeutics Sees Potential Hemophilia Cure Entering Clinic In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Gene integration technology would mean “once-a-lifetime treatment,” CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Wyeth’s Xyntha Wins FDA Nod For Hemophilia A
Factor VIII is made by modifying genes from Chinese hamster ovary cells to reduce infection risk.
Wyeth’s Xyntha Wins FDA Nod For Hemophilia A
Factor VIII is made by modifying genes from Chinese hamster ovary cells to reduce infection risk.
Pain Therapeutics Ends Year Flush, “Slightly Ahead” Of Alpharma
Abuse-deterrent pain drug market big enough for all, analyst tells “The Pink Sheet” DAILY.